Paroxysmal nocturnal haemoglobinuria
Top Cited Papers
- 18 May 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 3 (1), 1-14
- https://doi.org/10.1038/nrdp.2017.28
Abstract
Paroxysmal nocturnal haemoglobinuria (PNH) is a clonal haematopoietic stem cell (HSC) disease that presents with haemolytic anaemia, thrombosis and smooth muscle dystonias, as well as bone marrow failure in some cases. PNH is caused by somatic mutations in PIGA (which encodes phosphatidylinositol N-acetylglucosaminyltransferase subunit A) in one or more HSC clones. The gene product of PIGA is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. Clinical manifestations of PNH occur when a HSC clone carrying somatic PIGA mutations acquires a growth advantage and differentiates, generating mature blood cells that are deficient of GPI-anchored proteins. The loss of CD55 and CD59 renders PNH erythrocytes susceptible to intravascular haemolysis, which can lead to thrombosis and to much of the morbidity and mortality of PNH. The accumulation of anaphylatoxins (such as C5a) from complement activation might also have a role. The natural history of PNH is highly variable, ranging from quiescent to life-threatening. Therapeutic strategies include terminal complement blockade and bone marrow transplantation. Eculizumab, a monoclonal antibody complement inhibitor, is highly effective and the only licensed therapy for PNH.Keywords
This publication has 134 references indexed in Scilit:
- Paroxysmal nocturnal hemoglobinuria and concurrent JAK2V617F mutationBlood Cancer Journal, 2012
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatinJournal of Molecular Recognition, 2009
- The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for PatientsSeminars in Hematology, 2009
- Neutral evolution in paroxysmal nocturnal hemoglobinuriaProceedings of the National Academy of Sciences of the United States of America, 2008
- Harmful molecular mechanisms in sepsisNature Reviews Immunology, 2008
- Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseasesBone Marrow Transplantation, 2008
- Evidence for non-traditional activation of complement factor C3 during murine liver regenerationMolecular Immunology, 2008
- The Structure of OMCI, a Novel Lipocalin Inhibitor of the Complement SystemJournal of Molecular Biology, 2007